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qmul.ac.uk (R.W. Pickersgill).We show that the monomeric form of Shigella IpaH9.8 E3 ligase catalyses the ubiquitination of
human U2AF35 in vitro, providing a molecular mechanism for the observed in vivo effect. We fur-
ther discover that under non-reducing conditions IpaH9.8 undergoes a domain swap driven by the
formation of a disulﬁde bridge involving the catalytic cysteine and that this dimer is unable to cata-
lyse the ubiquitination of U2AF35. The crystal structure of the domain-swapped dimer is presented.
The redox inactivation of IpaH9.8 could be a mechanism of regulating the activity of the IpaH9.8 E3
ligase in response to cell damage so that the host cell in which the bacteria resides is maintained in a
benign state suitable for bacterial survival.
Structured summary:
MINT-7993779: ipaH9.8 (uniprotkb:Q8VSC3) and ipaH9.8 (uniprotkb:Q8VSC3) bind (MI:0408) by X-ray
crystallography (MI:0114)
MINT-7993812: ipaH9.8 (uniprotkb:Q8VSC3) and ipaH9.8 (uniprotkb:Q8VSC3) bind (MI:0407) by afﬁnity
chromatography technology (MI:0004)
MINT-7993790: ipaH9.8 (uniprotkb:Q8VSC3) and ipaH9.8 (uniprotkb:Q8VSC3) bind (MI:0407) by blue
native page (MI:0276)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction surrogate model, Shigella ﬂexneri IpaH9.8 inhibited MAPK kinaseThe IpaH family of proteins is of tremendous interest because
bacterial effectors produced by mammal, ﬁsh and plant pathogens
share several structural and functional characteristics with
members of this family. In essence, these effectors have a highly
conserved N-terminal leucine rich repeat domain, while their
conserved C-terminal region has been shown to have E3 ubiquitin
ligase activity [1]. IpaH9.8 has been shown to be secreted into the
host cell and targeted to the nucleus [2]. The crystal structures of
representatives of the IpaH family reveal the carboxy-terminal re-
gion to be a new family of E3 ubiquitin ligases [3,4]. In a yeastchemical Societies. Published by E
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Seyedarabi), r.w.pickersgill@dependent signaling by targeting components of this pathways
for degradation by the proteasome via the ubiquitination of
Ste7 [1]. Additional studies on the function of IpaH9.8 have
shown that this effector disrupts both NF-jD-dependent (nuclear
factor jD) gene expression and the activity of U2AF35, an alterna-
tive splicing factor, and shown that IpaH9.8 has an important role
in modulating host inﬂammatory responses [5]. A recent paper
provides evidence that IpaH9.8 dampens NF-jD mediated inﬂam-
matory responses by interacting with NEMO/IKKc (IjB kinase)
and ABIN-1 (a ubiquitin-binding adaptor protein) promoting
ABIN-1 polyubiquitination of NEMO leading to proteosome degra-
dation of NEMO and disruption of NF-jD signaling [6]. Here we
investigate if IpaH9.8 is able to ubiquitinate the auxiliary pre-
messenger ribonucleic acid (mRNA) splicing factor U2AF35. We
discover that the C-terminal region of IpaH9.8 can exist in vitro
as a monomer able to catalyse the ubiquitination of U2AF35
and as a dimer that does not possess this activity. Under non-
reducing conditions the sole cysteine of the C-terminal region of
IpaH9.8 forms an intermolecular disulﬁde bridge resulting in
the extension of an a-helix and formation of a domain-swapped
dimer. The involvement of the catalytic cysteine in the domain-
swapped dimer may be a method of regulating the activity oflsevier B.V. All rights reserved.
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a benign state.2. Materials and methods
2.1. Plasmids, antibodies, and reagents
We ampliﬁed the gene fragment of ipaH9.8 corresponding to
residues 254–545 by polymerase chain reaction using the con-
struct pGex2T::ipaH9.8(1–545) from strain YSH6000 (plasmid
pMYSH6000) as template. The ampliﬁed ipaH9.8 gene was cloned
into pET14b from Novagen (using NdeI and BamHI restriction
sites). The uba1 (E1) open reading frame was ampliﬁed from yeast
genomic DNA and cloned into pGex6P2 (using BamHI and XhoI
restriction sites). Sequencing conﬁrmed the plasmids were cor-
rectly constructed. His6-tagged Ubc5 (E2) enzyme from yeast
was produced as described [7]. The pGex4T::u2Af35 truncated
construct (corresponding to residues 43–146 with C67S mutant
of Human U2AF35 protein) was a generous gift from Clara
Kielkopf [8], of the Laboratories of Molecular Biophysics, The
Rockefeller University, New York, USA. Antibodies for glutathione
S-transferase (GST) and the two variants of hexahistidine (His)
antibodies comprising of the Mouse anti-His monoclonal antibody
and the hexahistidine-tag (His-tag) horse raddish peroxidase
(HRP) monoclonal antibody were purchased from Novagen, while
antibodies for HA and ubiquitin were obtained from Biomol. The
alkaline phosphotase and HRP conjugated secondary antibodies
were also purchased from Novagen, except for the Infrared dye
labeled secondary antibodies IRDye 800CW and IRDye 680 used
for the Odyssey infrared imaging system which was supplied by
LI-COR Biosciences. All the ubiquitin variant proteins were pur-
chased from Biomol including the wild type (WT), methylated
(Me) and six lysine mutated variants (K6-, K11-, K29-, K33-,
K48-, K63-only ubiquitins). All other reagents used were pur-
chased from Sigma–Aldrich.
2.2. Expression and puriﬁcation of recombinant proteins
The His6-tagged IpaH9.8254–545 protein was expressed and
over-produced in BL21(DE3) strain (Novagen) at 37 C for 3–4 h
until the optical density at 600 reached 0.6–0.8. The cells were
then induced with 0.5 mM IPTG at 30 C overnight. The cell pellet
was resuspended in 25 mM Tris–HCl, pH 8.0 (4 C), 500 mM NaCl
and 20 mM imidazole and frozen at 80 C. The frozen pellet was
subsequently thawed and sonicated. The soluble protein fraction
was harvested by centrifugation and loaded onto a nickel chelat-
ing sepharose column, equilibrated at 4 C with buffer A consist-
ing of 25 mM Tris HCl, pH 8.0 (4 C), 500 mM NaCl and 20 mM
imidazole. His6-tagged IpaH9.8254–545 protein was eluted on a
gradient of 0–100% (v/v) buffer B composed of 25 mM Tris–HCl,
pH 8.0 (4 C), 500 mM NaCl and 500 mM imidazole. Samples of
His6-tagged IpaH9.8254–545 protein from two overlapping peaks
eluted from the nickel chelating sepharose column were assessed
by sodium dodecyl sulphate (SDS)–PAGE using standard 1 SDS
loading buffer consisting of 10% glycerol, 0.1% Bromophenol Blue,
50 mM Tris HCl, pH 6.8 room temperature (RT) and 2% SDS, in the
presence or absence of 100 mM Dithiotheritol (DTT), and selec-
tively pooled and loaded onto the superdex 200 size exclusion
column equilibrated with 50 mM Tris HCl, pH 7.4 (RT) in order
to separate the monomeric form from the dimer. His6-tagged
Ubc5 (E2) protein was also produced and puriﬁed using the same
protocol mentioned above. GST-tagged IpaH9.81–545 and GST-
tagged U2AF3543–146 proteins were expressed and over-produced
using the same method described for His6-tagged IpaH9.8254–545with the difference that they were puriﬁed using standard gluta-
thione sepharose batch puriﬁcation method. The GST tag of GST-
tagged IpaH9.81–545 was cleaved on the column by addition of
thrombin (Novagen) while retaining the GST-tag of U2AF35 for
use in detection in western blot analysis. All proteins were fur-
ther puriﬁed on the size exclusion column and stored in 50 mM
Tris–HCl, pH 7.4 (RT) to be used in ubiquitination assays. GST-
tagged Uba1 (E1) was expressed in BL21-codon plus cells with
low temperature induction overnight at 16 C and then puriﬁed
using standard glutathione sepharose batch puriﬁcation, followed
by cleavage of the GST-tag.2.3. In vitro ubiquitination assays
Ubiquitination assays were in 30 ll reaction buffer (50 mM
Tris–HCl, pH 7.4 (RT), 10 mM MgCl2 and 10 mM ATP) containing
300 ng of Uba1 (E1), 600 ng of Ubc5 (E2), 1–3 lg of ubiquitin.
The following concentrations of proteins were used in the assays;
1 lg of His6-tagged IpaH9.8254–545 (E3) either in its monomeric or
dimeric form or 1 lg of GST-cleaved IpaH9.81–545 (E3) in the pres-
ence or absence of 7 lg of GST-U2AF3543–146 protein. Reactions
were incubated at 30 C for 1 h and terminated with the addition
of SDS–PAGE sample buffer (consisting of 10% glycerol, 0.1% Bro-
mophenol Blue, 50 mM Tris–HCl, pH 6.8 and 2% SDS) in the pres-
ence or absence of 100 mM DTT, followed by boiling of the
samples at 100 C for 10 min and their subsequent storage at
20 C. To retain the monomer upon storage, stocks of the mono-
meric form was stored at 80 C in the presence of 1–2 mM of
the strong reducing agent Tris (2-carboxyethyl) phosphine hydro-
chloride, TCEP (Fluka). This prevented the monomeric species to
convert into the dimer. Each time the monomeric form of His6-
tagged IpaH9.8254–545 was used in a ubiquitination assay, the
TCEP treated protein was dialyzed against a large volume of buf-
fer consisting of 0.5 mM DTT (Fisher, Bioreagents) and 50 mM
Tris–HCl, pH 7.4 (RT) to remove the TCEP but retain a small con-
centration of the reducing agent DTT. The samples of the ubiqui-
tination assays were analyzed by western blotting using the
appropriate antibody.2.4. Crystallization and data collection of the IpaH9.8254–545 dimer
His6-tagged IpaH9.8254–545 was concentrated to 20 mg ml1 in
a buffer containing 25 mM Tris–HCl, pH 7.5 (RT) and 100 mM
NaCl. Initial screens resulted in crystals in a number of condi-
tions from the Hampton research Crystal screens I and II, with
the best diffracting crystals grown from Crystal screen I, condi-
tion 22, consisting of 0.2 M sodium acetate trihydrate, 0.1 M
Tris–HCl, pH 8.5 and 30% polyethylene glycol 4000. Further
screening around this condition did not yield better diffracting
crystals. The reservoir conditions augmented with 10% (v/v) eth-
ylene glycol was the optimal cryoprotectant tested. All crystalli-
zation experiments used the hanging drop vapor diffusion
method at 19 C. Data were collected at DLS (Diamond Light
Source, Oxfordshire, UK) using beamline I04, a wavelength of
0.9716 Å, and the crystal at 100 K. The diffraction data were pro-
cessed using MOSFLM [9] and SCALA [10]. Heavy metal soaked
crystals of IpaH9.8254–545 were tested including the heavy metal
methylmercury chloride. No signiﬁcant isomorphous or anoma-
lous signal could be detected which suggested the cysteine in
IpaH9.8254–545 was not accessible for modiﬁcation. Attempts to
crystallize IpaH9.8254–545 protein in its monomeric form in the
presence of a strong reducing agent, TCEP (1 mM ﬁnal concentra-
tion), were not successful. Data were collected from Se-Met la-
beled crystals to a maximum resolution of 5.5 Å.
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IpaH9.8254–545 dimer
Data at 3.2 Å were processed and reduced using MOSFLM [9]
and SCALA from the CCP4 suite [10], solved using MOLREP [11],
and reﬁned and visualized using REFMAC5/CNS [12,13] and COOT
[14] (crystallographic data statistics are given in Table 1). The
space group was P6222 with a = 92.7 Å and c = 135.6 Å with one
molecule in the asymmetric unit. The search model used in molec-
ular replacement was Chain C from the structure of IpaH1.4 (pro-
tein data bank (PDB) entry: 3ckd). The correlation coefﬁcients,
and R-factors in parentheses, of the solution and second unrelated
peak were 0.416 (60.9%) and 0.357 (64.2%), respectively. The pres-
ence of ﬁve Se peaks at the positions of the methionines in the
5.5 Å resolution anomalous difference map at 5r or above con-
ﬁrmed that the molecular replacement solution was correct. The ﬁ-
nal structure comprises residues 253–298, 302–390, 398–417 and
427–534 with the three breaks in the polypeptide chain corre-
sponding to ﬂexible loop regions not seen in the electron densityTable 1
Crystallographic data and reﬁnement statistics.
Data collection Native Se-Met
Space group P6222 P6222
a, b, c (Å) a = b = 92.6,
c = 135.6
a = b = 91.5,
c = 135.8
a, b, c () a = b = 90.0,
c = 120.0
a = b = 90.0,
c = 120.0
Molecular mass in Da (residues) 35,688.6 (313)a 35,923.1 (313)a
Molecule per asymmetric unit,
AU
1 1
Se-Met (AU) 0 5
Wavelength (Å) 1.045 0.980
Resolution (Å) 38.46–3.20 (3.37–
3.20)a
79.31–5.50 (5.80–
5.50)a
Number of unique reﬂections 5984 (785)a 1278(177)a
Multiplicity 9.1 (9.2)a 10.2 (10.8)a
Completeness (%) 97.6 (91.8)a 99.8 (100)a
Rsym (%)b 0.083 (0.530)a 0.091 (0.451)a
Mean I/sigma (I) 21.7 (4.2)a 22.1 (5.9)a
Rpim (%)c 0.028 (0.177)a 0.032 (0.145)a
Rmeas (%)d 0.088 (0.559)a 0.108 (0.487)a
MSANe 1.503
Wilson B-factor (Å2) 76.0 174.0
Reﬁnement
Resolution (Å) 34.53–3.20
Reﬂections (work/test) 5689/268
R-factor/R-free (%)f 28.9/31.1
rmsd bond length (Å)/angle () 0.0056/0.848
No. of protein atoms/mean B-
factor (Å2)
2110/86.0
Ramachandran plot statistics (%)
Residues in most favored
regions
93.0
Residues in additional allowed
regions
5.8
Residues in generously allowed
regions
0.8
Residues in disallowed regions 0.4
a The parameter values for the range 3.37–3.20 Å and 5.80–5.50 Å are given in
parentheses for native and Se-Met data, respectively.
b Rsym = Rhkl RI |Ii  <I>|/Rhkl RIi, where Ii is the intensity of the ith observation,
<I> is the mean intensity of the reﬂection, and the summations extend over all
unique reﬂections (hkl) and all equivalents (i), respectively.
c Rpim is a measure of the quality of the data after averaging the multiple
measurements [21].
d Rmeas (also known as Rrim) is an improved version of the traditional Rmerge
(Rsym) and measures how well the different observations agree [21].
e MSAN is the mid slope of anomalous normal probability.
f R-factor = Rhkl |Fo  Fc|/Rhkl Fo, where Fo and Fc represent the observed and
calculated structure factors, respectively. The R-factor is calculated using 95% of the
data included in reﬁnement and R-free the 4.5% excluded. The values presented in
this Table come from SCALA [10], REFMAC [13], PROCHECK and MR-ANALYSE from
CCP4 suite. [10].map. The C-terminal 11 residues and the N-terminal His tag, apart
from the Ser, are also not seen in the electron density map. Because
of the modest resolution and high Wilson B-factor the structure
was reﬁned with tight stereochemical restraints. MOLPROBITY
[15] suggests >99% of residues are in allowed regions with three
outliers. Reﬁnement using the TLS option in PHENIX [16] gave sim-
ilar results. Contacts were calculated using PISA [17] and electro-
static potentials using DELPHI [18].
3. Results and discussion
3.1. Non-reduced IpaH9.8 forms a disulﬁde-linked dimer in vitro
Both full-length IpaH9.8 (residues 1-545) and C-terminal
IpaH9.8 (residues 254-545) can exist as monomer and disulﬁde-
linked dimer in vitro as assessed by several techniques including
afﬁnity chromatography, gel ﬁltration chromatography, SDS–PAGE,
Native-PAGE and dynamic light scattering. Dimerization was ini-
tially detected using full-length IpaH9.81–545 assessed by native-
PAGE without the addition of reducing agent (Fig. 1a). SDS–PAGE
analysis under reducing and non-reducing conditions conﬁrmed
the presence of an approximately 60 kDa monomer and 120 kDa
disulﬁde-linked dimer. Dynamic light scattering conﬁrmed the
existence of the dimer. Under non-reducing conditions it was pos-
sible to purify the IpaH9.8254–545 dimer and under reducing condi-
tions the monomer exclusively (Fig. 1b). This result shows that
there is an intermolecular disulﬁde in the dimer and as the C-ter-
minal domain has only one cysteine (Cys 337) the disulﬁde is un-
iquely deﬁned. The dimer with two His-tags eluted from the nickel
afﬁnity column at a higher imidazole concentration than did the
monomer (Fig. 1c).Native-PAGE          α-His    
64 
36 
50 
MW (KDa) 
98 
98 
64 
148 
50 
IpaH9.8254-545
DTT   +  - 
IpaH9.81-545
MW (KDa) 
Monomer Dimer 
Affinity column 
1500 100 
0 
% imidazole 
0 
A280
mAU 
a
c
b
Fig. 1. Full-length IpaH9.8 and the C-terminal domain of IpaH9.8 can exist as
monomer and dimer. (a) Coomassie stained Native-PAGE of IpaH9.81–545 (full-
length) reveals two bands, the lower corresponds to monomer and the upper to
dimer. (b) Western blot analysis of His6-tagged IpaH9.8254–545 (C-terminal domain)
shows the presence of monomer in reducing conditions and dimer in non-reducing
conditions. The gel was probed using an anti-His tag polyclonal antibody. (c) The
dimer with two hexahistidine tags elutes from the nickel afﬁnity column at a higher
imidazole concentration than does monomer with its single His-tag. The imidazole
gradient is shown, as a percentage of 500 mM, along with the sample absorption at
280 nm in milli-absorbance units.
a 
IpaH9.8 Monomer +  +  +   +    
GST-U2AF3543-146   -  -  +   +    
WT Ubiquitin      -  +  -   +    
α-GST 
b 
IpaH9.8 Dimer +  +   +   +    
GST-U2AF3543-146   -  -   +   +      
WT Ubiquitin      -  +   -   +    
α-GST 
c 
IpaH9.81-545      +   +   +   +  +   +
GST-U2AF3543-146      -   -   +   -  -   +
His-WT ubiquitin -   +   +   -  +   + 
SDS-PAGE α-His 
MW (KDa) 
GST-U2AF35
Ub-IpaH9.81-545
IpaH9.81-545
MW (KDa) 
GST-U2AF35
MW (KDa) 
Fig. 2. Human U2AF35 splicing factor is a substrate for S. ﬂexneri IpaH9.8 E3 ubiquitin ligase. (a) The monomeric form of His6-tagged IpaH9.8254–545 is able to ubiquitinate
GST-U2AF35 (residues 43-146, C67S) in vitro (bands representing ubiquitinated forms of GST-U2AF35 are shown with asterisks). (b) The dimeric form of IpaH9.8254–545,
however, does not ubiquitinate U2AF35. Samples were analyzed by western blot analysis using Mouse anti-GST tag monoclonal antibody. (c) Analysis of the full-length
IpaH9.8 protein residues 1–545 reveals that the auto-ubiquitination activity of the full-length protein is gained in the presence of GST-U2AF35. This result was assessed both
using SDS–PAGE (left panel) and western blot (right panel) analyses. The western blot analysis used Mouse anti-His monoclonal antibody to detect His-tagged ubiquitin.
IpaH9.8 Monomer  +  +  +  +  +  +  +  +   +  + 
Ubiquitin  -  WT  Me  K6 K11 K27 K29 K33 K48 K63
α-Ubiquitin 
MW (KDa) 
Fig. 3. The auto-ubiquitination activity of monomeric His6-tagged IpaH9.8254–545
assessed using a range of ubiquitins. Wild-type (WT) ubiquitin, ubiquitin with all
seven lysines methylated (Me), and seven lysine variants of ubiquitin (K6-, K11-,
K27-, K29-, K33-, K48-, K63-only ubiquitins where K6 has only lysine 6, K11 only
lysine 11, and so on for the other ﬁve mutants) revealed chain formation primarily
on K6, K11, K29, K33, to a lesser extent on K48, very little on K27 and none on K63.
The extent of poly-ubiquitin chain formation is greatest with WT ubiquitin
suggesting that mixed-linkage chains may be formed. While only the mono-
ubiquitinated form of His6-tagged IpaH9.8254–545 was apparent (in assays contain-
ing methylated and seven lysine variants of ubiquitin) using anti-His antibody, the
use of the anti-ubiquitin antibody revealed chain formation as seen in the ﬁgure.
The western blot analysis used rabbit anti-ubiquitin polyclonal antibody.
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factor
Human U2AF35 is a nuclear auxiliary factor essential in the
splicing of pre-mRNA to mRNA. We previously showed that
U2AF35 (residues 43–146, C67S) interacted with IpaH9.8254–545
[5], here we discover that the same region is ubiquitinated by
the IpaH9.8254–545 subunit (Fig. 2a). The two higher molecular
weight bands detected by western blot analysis using WT ubiqui-
tin, corresponding to ubiquitinated GST-U2AF35, could be due to
ubiquitination at two sites or chain formation at one site on
U2AF35 (Fig. 2a). The persistence of both bands using Me ubiquitin,
which cannot form poly-ubiquitin chains, reveals this to be ubiqui-
tination at two distinct sites (data not shown). The dimeric form of
IpaH9.8254–545 did not ubiquitinate U2AF35 (Fig. 2b). Intriguingly,
the auto-ubiquitination activity of the full-length IpaH9.8 was
dependent on the presence of U2AF35 (Fig. 2c). Similar behavior
was observed by Singer et al. (2008) [3], who showed that full-
length IpaH9.8 required the presence of its yeast substrate Ste7
to show a corresponding level of auto-ubiquitination activity to
that of the C-terminal domain. The authors suggested that the N-
terminal domain may be inhibitory for the auto-ubiquitination
activity of the full-length IpaH9.8 and that substrate binding re-
leases this inhibition. This substrate release of inhibition is also
apparent in our experiment with full-length IpaH9.8 and its human
substrate U2AF35.
3.3. Monomeric IpaH9.8254–545 primarily makes K6, K11, K29 and K33
poly-ubiquitin chains
The type and number of poly-ubiquitin chains that are conju-
gated to a target is highly regulated to generate distinct signals
that affect different physiological processes, since not only cantargets be mono-ubiquitinated or poly-ubiquitinated, but also dif-
ferent types of poly-ubiquitin chains can be formed [19]. While the
most abundant chain species are K48-linked and K63-linked poly-
ubiquitins which have been studied widely with functions attrib-
uted to them through studies involving speciﬁc targets that lead
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nents in the host cell, chain formation on other lysine residues of
ubiquitin are less well understood. Here we demonstrate that
IpaH9.8254–545 primarily makes K6, K11, K29 and K33-linked
chains and to a lesser extent K48 and K27-linked chains in an
auto-ubiquitination assay (Fig. 3) which when translated to its tar-
get U2AF35, may indicate that chain formation on lysine residues
other than K48 may describe a different recognition process, other
than proteasome-dependent proteolysis. In addition, the auto-
ubiquitination activity of IpaH9.8254–545 is greater in the presence
of WT ubiquitin, since ubiquitinated protein with larger molecular
weight is detected upon use of the WT ubiquitin, compared to that
of the six lysine mutated variants (K6, K11, K29, K33, to a lesser ex-Fig. 4. The crystal structure of the domain-swapped IpaH9.8 dimer. (a) Cartoon represent
chains are related by a crystallographic twofold axis. The structure of IpaH1.4 CTR (chain A
polypeptide chain of IpaH9.8 (dimer) and IpaH1.4 (monomer) are shown together to reve
(residues 284–349; helix a1 through to a4). (c) Compared to IpaH1.4, the ﬂexible loo
cysteines in the domain-swapped dimer are brought close together. The N-terminal dom
3.2 Å resolution rA-weighted 2Fo  Fc Fourier synthesis contoured at 1r showing the evi
disulﬁde with and its dimer related symmetry equivalent in the crystal structure of the Ip
subunit with the a-carbon backbone drawn as a ribbon and surface colored according to e
occasional positive potential (blue) proximal to arginines and less frequently lysines. The
domain is indicated. The extended helix of the twofold related subunit is drawn as a ca
swapped dimer include the disulﬁde between the extended a-helices and the hydrophob
and DELPHI [18].tent K48 and very little K27) indicating that although IpaH9.8254–545
appears to be making different types of homotypic chains (using
the same lysine residue in ubiquitin for conjugation), the possibil-
ity that it may also be making mixed-linkage chains i.e. utilizing
the different lysines to connect consecutive ubiquitin moieties,
cannot be discounted.
3.4. Crystal structure of the IpaH9.8254–545 dimer reveals a
domain-swap
Crystallization of full-length IpaH9.8 and monomeric
IpaH9.8254–545 was not achieved, but crystals of the dimeric form
of IpaH9.8254–545 which diffracted to 3.2 Å with a Wilson B-factoration of the domain-swapped IpaH9.8 dimer in the crystal (cyan and green). The two
in magenta) is superimposed on one of the chains of the IpaH9.8 dimer. (b) A single
al the extension of helix a5 into a6 resulting in swapping of the N-terminal domain
p including the conserved cysteine becomes helical in conformation and the two
ain rotates through approximately 176 and is translated by approximately 9 Å. (d)
dence for the extended a-helix and the location of the conserved cysteine forming a
aH9.8 dimer. (e) Schematic representation of the C-terminal domain of the IpaH9.8
lectrostatic potential. The surface is predominantly acidic (red) punctuated with the
side chains of the Asp and Cys of the CXD motif are drawn as sticks, the N-terminal
rtoon across the surface of the subunit. (f) Key interactions stabilizing the domain-
ic cluster around Trp 376. The panels in this ﬁgure were produced using PYMOL [20]
4168 A. Seyedarabi et al. / FEBS Letters 584 (2010) 4163–4168of 76 Å2 were grown. These crystals had a single IpaH9.8254–545
molecule in the asymmetric unit. Se-Met labeled crystals were ob-
tained under similar crystallization conditions but diffracted to
only 5.5 Å. We were able to solve the dimeric structure using the
structure of IpaH1.4 C-terminal domain [3] (PDB entry: 3ckd) using
the C-chain as a search model in molecular replacement calcula-
tions. The molecular replacement solution was conﬁrmed by com-
paring the predicted positions of the ﬁve selenium atoms with the
anomalous difference map calculated using the SAD data collected
from Se-Met labeled crystals. It was immediately clear from the
ﬁrst electron density map examined that, compared to the struc-
ture of IpaH1.4, helix a5 of IpaH9.8 was extended resulting in a
swap of the N-terminal domain (formed by helix a1 through to
a4) with the twofold symmetry related molecule in the crystal
resulting in a domain-swapped dimer (Fig. 4a). In the domain-
swapped structure the 8-residue ﬂexible loop of IpaH1.4, residues
333–340 harboring the catalytic cysteine (Cys 337), connecting
a5–a6 in the IpaH1.4 structure becomes helical such that a5 and
a6 form a single 39-residue long helix in the IpaH9.8 structure
(Fig 4b and c). This results in a substantial structural rearrange-
ment of the N-terminal sub-domain with respect to the rest of
the molecule and a reduction in ﬂexibility of the polypeptide har-
bouring the conserved CXD sequence of the IpaH family. The
change in conformation from loop to helix moves the N-terminal
domain of IpaH9.8 by a rotation of approximately 176 and a trans-
lation of 9 Å and brings the SG atom of Cys 337 and its dimer re-
lated equivalent into close proximity so they can form a disulﬁde
bond (Fig. 4d). The accessible surface area buried on dimerization
is only 1448 Å2, a relatively low fraction (8.8%) of the total accessi-
ble surface of the IpaH9.8 molecule. This highlights the importance
of the disulﬁde in driving the domain swap (Fig. 4e) in agreement
with the solution behavior of IpaH9.8 where the dimer does not
form under reducing conditions. A buried hydrophobic cluster sta-
bilizes the domain swap and involves Trp 376 from the extended
a5/a6-helix of one subunit packing into a hydrophobic pocket
formed by residues from the anti-parallel packing of helices a3
and a4 of the other subunit. The residues forming the pocket into
which Trp 376 packs include Trp 312, Phe 286, Phe 289, Phe 305
and Leu 293 (Fig. 4f). The packing is the same in the monomer
but involves Trp 376 from the same subunit. Protein coordinates
and structure factor amplitudes are available from the protein
databank as entry 3L3P.
4. Conclusion
We have shown that IpaH9.8 can ubiquitinate human U2AF35
using an in vitro assay, this provides a plausible explanation for
its previously observed disruption of pre-mRNA splicing in vivo.
Furthermore, we have shown that domain swapping in response
to oxidizing conditions switches off IpaH9.8 E3 ligase activity. Reg-
ulating the activity of IpaH9.8 in response to the level of damage to
the host cell may be a way to maintain the cell in a benign state
suitable for bacterial survival, the cell is not dead nor is it able to
mount an attack on the invading bacteria.Acknowledgements
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